Prescott Group Capital Management L.L.C. Has $1.55 Million Stake in Enhabit, Inc. (NYSE:EHAB)

Prescott Group Capital Management L.L.C. lowered its holdings in Enhabit, Inc. (NYSE:EHAB) by 1.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 198,412 shares of the company’s stock after selling 2,038 shares during the period. Prescott Group Capital Management L.L.C.’s holdings in Enhabit were worth $1,550,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new position in Enhabit during the 4th quarter worth about $124,000. Versor Investments LP raised its stake in shares of Enhabit by 135.0% in the fourth quarter. Versor Investments LP now owns 28,900 shares of the company’s stock worth $226,000 after acquiring an additional 16,600 shares during the last quarter. Paradice Investment Management LLC lifted its position in shares of Enhabit by 12.8% during the fourth quarter. Paradice Investment Management LLC now owns 1,780,113 shares of the company’s stock worth $13,903,000 after purchasing an additional 201,997 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Enhabit by 2.8% during the fourth quarter. Rhumbline Advisers now owns 80,760 shares of the company’s stock valued at $631,000 after purchasing an additional 2,211 shares during the last quarter. Finally, Stoneridge Investment Partners LLC grew its stake in shares of Enhabit by 22.6% during the fourth quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company’s stock valued at $98,000 after purchasing an additional 2,308 shares during the last quarter.

Enhabit Price Performance

EHAB opened at $8.05 on Friday. The company has a fifty day moving average price of $8.18 and a two-hundred day moving average price of $7.90. The firm has a market capitalization of $404.53 million, a PE ratio of -3.47 and a beta of 1.80. Enhabit, Inc. has a 52 week low of $6.85 and a 52 week high of $11.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EHAB. Leerink Partners reaffirmed a “market perform” rating and set a $8.00 price objective (down previously from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group raised Enhabit from a “hold” rating to a “buy” rating and upped their price target for the company from $8.25 to $9.50 in a research note on Monday, December 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.75.

Insider Transactions at Enhabit

In other news, Director Stuart M. Mcguigan purchased 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the transaction, the director now directly owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. The trade was a 47.15 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey Bolton acquired 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $8.69 per share, with a total value of $34,760.00. Following the acquisition, the director now owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. This trade represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is owned by corporate insiders.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.